The approval allows Nuformix to initiate the first dosing of NXP001 in an open-label study to compare the bioavailability of NXP001 to Merck’s EMEND in healthy subjects. Nuformix
The expanded Farxiga and Xigduo XR labels have been approved to treat patients with T2D and moderate renal impairment, which is a chronic kidney disease with an estimated
Based in Cambridge of Massachusetts, Anthos Therapeutics will develop and commercialize genetically and pharmacologically validated therapies for high-risk cardiovascular patient populations. Anthos chairman and Blackstone Life Sciences head
“As we continue to transform Bausch Health, we are now pivoting to offense with research investments and strategic acquisitions that augment our core businesses. We are excited to
TQJ230 was discovered by Ionis and has been co-developed to date by Akcea and Ionis. Novartis is now responsible for worldwide development and commercialization of this asset. Millions
Danaher seeks to help its customers solve complex challenges and enhance quality of life across the world. GE Biopharma offers instruments, consumables, and software to facilitate research, discovery,
Urovant plans to use the proceeds to fund ongoing development of its lead compound vibegron, for business development opportunities, and for general corporate purposes. “This financing provides Urovant
As part of an exclusive, global strategic collaboration and option agreement, AbbVie and Voyager will develop and commercialize vectorized antibodies directed at pathological species of alpha-synuclein to treat Parkinson’s
Johnson & Johnson Innovation facilitated the transaction. The collaboration focuses on several undisclosed integrin targets and will explore both inhibitors and activators of integrin function. To date, Morphic
As per terms of the deal, Merck’s subsidiary will pay $5.85 per share to purchase all outstanding shares of Immune Design. Immune Design has next-generation in vivo approaches,
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.